These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34076303)

  • 1. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
    Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
    J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
    Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
    Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
    van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates.
    Majoor BCJ; Papapoulos SE; Dijkstra PDS; Fiocco M; Hamdy NAT; Appelman-Dijkstra NM
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6069-6078. PubMed ID: 31390018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
    Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
    J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
    Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
    Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
    Trojani MC; Gensburger D; Bagouet F; Cortet B; Couture G; Marcelli C; Mehsen Cetre N; Breuil V; Chapurlat R
    Bone; 2023 Sep; 174():116819. PubMed ID: 37301527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.
    Florenzano P; Pan KS; Brown SM; Paul SM; Kushner H; Guthrie LC; de Castro LF; Collins MT; Boyce AM
    J Bone Miner Res; 2019 Apr; 34(4):653-660. PubMed ID: 30645769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
    Valadares LP; de Araújo Ferreira BS; da Cunha BM; Moreira LA; Batista FGA; da Fonseca Hottz C; Magalhães GGR
    Arch Endocrinol Metab; 2022 Apr; 66(2):247-255. PubMed ID: 35420267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab treatment for fibrous dysplasia.
    Boyce AM; Chong WH; Yao J; Gafni RI; Kelly MH; Chamberlain CE; Bassim C; Cherman N; Ellsworth M; Kasa-Vubu JZ; Farley FA; Molinolo AA; Bhattacharyya N; Collins MT
    J Bone Miner Res; 2012 Jul; 27(7):1462-70. PubMed ID: 22431375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial.
    Chapurlat R; Gensburger D; Trolliet C; Rouanet S; Mehsen-Cetre N; Orcel P
    Bone; 2022 Apr; 157():116343. PubMed ID: 35104665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
    Burckhardt P; Faouzi M; Buclin T; Lamy O;
    J Bone Miner Res; 2021 Sep; 36(9):1717-1728. PubMed ID: 34009703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis.
    Bertin H; Moussa MS; Komarova S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1103-1119. PubMed ID: 37632645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature.
    Nadella S; Mupparapu M; Akintoye SO
    Quintessence Int; 2022 Jun; 53(7):616-623. PubMed ID: 35674165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects.
    Raborn LN; Burke AB; Ebb DH; Collins MT; Kaban LB; Boyce AM
    Osteoporos Int; 2021 Sep; 32(9):1889-1893. PubMed ID: 33772327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coxa Vara Deformity in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History and Risk Factors: A Two-Center Study.
    Meier ME; Appelman-Dijkstra NM; Collins MT; Geels RES; Stanton RP; de Witte PB; Boyce AM; van de Sande MAJ
    J Bone Miner Res; 2023 Jul; 38(7):968-975. PubMed ID: 37102469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
    Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
    Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
    Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
    J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.
    Palmisano B; Spica E; Remoli C; Labella R; Di Filippo A; Donsante S; Bini F; Raimondo D; Marinozzi F; Boyde A; Robey P; Corsi A; Riminucci M
    J Bone Miner Res; 2019 Dec; 34(12):2171-2182. PubMed ID: 31295366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.